PMID- 31452755
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231104
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 18
IP  - 3
DP  - 2019 Sep
TI  - Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese 
      patients.
PG  - 2771-2776
LID - 10.3892/ol.2019.10612 [doi]
AB  - Cervical cancer is one of the leading causes of cancer-associated mortality among 
      females; however, the underlying molecular mechanisms of its carcinogenesis 
      remain largely unclear. Previous comprehensive genomic studies have revealed 
      prevalent estrogen receptor 1 (ESR1) mutations in breast cancer, which are rare 
      in certain other types of cancer. To the best of our knowledge, it is unknown 
      whether ESR1 mutations also exist in cervical cancer. Considering the evidence 
      that cervical cancer shares certain genetic aberrations with breast cancer, and 
      that the progression of both breast and cervical cancers can be affected by 
      estrogen, it is possible that cervical cancer may also harbor ESR1 mutations. In 
      the present study, a total of 260 Chinese cervical cancer samples with distinct 
      subtypes were tested for the presence of ESR1 mutations. A total of three 
      heterozygous missense ESR1 mutations, p.K303R (c.908A>G), p.T311M (c.932C>T) and 
      p.Y537C (c.1610A>G), were identified in 3/207 (1.4%) cervical squamous cell 
      carcinoma samples, which were absent in 27 adenosquamous carcinomas and 26 
      adenocarcinomas samples. Of the three individuals with an ESR1mutation, 1 patient 
      was also diagnosed with ovarian endometriosis and the other 2 patients were 
      diagnosed with a uterine fibroid. A bioinformatics analysis suggested that these 
      ESR1 mutations may be pathogenic by promoting the development of cervical cancer. 
      Furthermore, a previous comprehensive study confirmed that individuals with 
      cervical squamous cell carcinoma possessed ESR1 mutations. These combined studies 
      indicate that ESR1 mutations may participate in the carcinogenesis of cervical 
      squamous cell carcinoma, albeit at a low frequency. In conclusion, the present 
      study identified three potentially pathogenic ESR1 mutations in Chinese cervical 
      squamous cell carcinoma samples, but not in other subtypes.
FAU - Yang, Xin-Min
AU  - Yang XM
AD  - College of Medicine, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
AD  - Key Laboratory of Women's Reproductive Health of Jiangxi Province, Jiangxi 
      Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. 
      China.
FAU - Wu, Zhi-Min
AU  - Wu ZM
AD  - Department of Management Engineering, Shangrao Vocational and Technical College, 
      Shangrao, Jiangxi 334109, P.R. China.
FAU - Huang, Huang
AU  - Huang H
AD  - Department of Cardiac Surgery, The First Affiliated Hospital, Nanchang 
      University, Nanchang, Jiangxi 330006, P.R. China.
FAU - Chu, Xiao-Yan
AU  - Chu XY
AD  - Department of Gynecological Oncology, Jiangxi Provincial Cancer Hospital, 
      Nanchang, Jiangxi 330029, P.R. China.
FAU - Lou, Jun
AU  - Lou J
AD  - Department of Gynecological Oncology, Jiangxi Provincial Cancer Hospital, 
      Nanchang, Jiangxi 330029, P.R. China.
FAU - Xu, Li-Xian
AU  - Xu LX
AD  - College of Medicine, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
AD  - Key Laboratory of Women's Reproductive Health of Jiangxi Province, Jiangxi 
      Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. 
      China.
FAU - Chen, Yuan-Ting
AU  - Chen YT
AD  - College of Medicine, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
AD  - Key Laboratory of Women's Reproductive Health of Jiangxi Province, Jiangxi 
      Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. 
      China.
FAU - Wang, Li-Qun
AU  - Wang LQ
AD  - College of Medicine, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
AD  - Key Laboratory of Women's Reproductive Health of Jiangxi Province, Jiangxi 
      Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. 
      China.
FAU - Huang, Ou-Ping
AU  - Huang OP
AD  - College of Medicine, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
AD  - Key Laboratory of Women's Reproductive Health of Jiangxi Province, Jiangxi 
      Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. 
      China.
LA  - eng
PT  - Journal Article
DEP - 20190715
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6676661
OTO - NOTNLM
OT  - Chinese
OT  - cervical cancer
OT  - estrogen receptor 1
OT  - mutation
EDAT- 2019/08/28 06:00
MHDA- 2019/08/28 06:01
PMCR- 2019/07/15
CRDT- 2019/08/28 06:00
PHST- 2018/03/26 00:00 [received]
PHST- 2019/04/04 00:00 [accepted]
PHST- 2019/08/28 06:00 [entrez]
PHST- 2019/08/28 06:00 [pubmed]
PHST- 2019/08/28 06:01 [medline]
PHST- 2019/07/15 00:00 [pmc-release]
AID - OL-0-0-10612 [pii]
AID - 10.3892/ol.2019.10612 [doi]
PST - ppublish
SO  - Oncol Lett. 2019 Sep;18(3):2771-2776. doi: 10.3892/ol.2019.10612. Epub 2019 Jul 
      15.